TACT908

TACT908

Clinical data
Other names	TACT-908; Compound 28-12; 2ZEDMA; [2-(Indolizin-1-yl)ethyl]dimethylamine; Indolizine-DMT
Drug class	Serotonin receptor agonist; Serotonin 5-HT1B receptor agonist; Non-hallucinogenic serotonin 5-HT2A receptor agonist
Identifiers
IUPAC name 2-indolizin-1-yl-N,N-dimethylethanamine
PubChem CID	169203122
Chemical and physical data
Formula	C12H16N2
Molar mass	188.274 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(C)CCC1=C2C=CC=CN2C=C1
InChI InChI=1S/C12H16N2/c1-13(2)9-6-11-7-10-14-8-4-3-5-12(11)14/h3-5,7-8,10H,6,9H2,1-2H3 Key:CBZZXMYTGARRHB-UHFFFAOYSA-N

TACT908, also known as [2-(indolizin-1-yl)ethyl]dimethylamine (2ZEDMA), is a serotonin receptor agonist of the indolizinylethylamine family which is under development for the treatment of cluster headaches.¹²³ It is a positional isomer of the tryptamine serotonergic psychedelic N,N-dimethyltryptamine (DMT) in which the indole ring has been replaced with an indolizine ring.¹

The drug acts as a serotonin 5-HT_1B and 5-HT_2A receptor agonist.¹³ Its EC₅₀Tooltip half-maximal effective concentration at the serotonin 5-HT_2A receptor is 52 nM (E_maxTooltip maximal efficacy ≈ 30% of that of serotonin) and its EC₅₀ at the serotonin 5-HT_1B receptor is 143 nM.¹ TACT908 is said to be a non-hallucinogenic serotonin 5-HT_2A receptor agonist.¹³ It showed little or no activity at 45 other screened targets, including the serotonin 5-HT_1A, 5-HT_2B, and 5-HT₃ receptors as well as the monoamine transporters (MATs).¹ Other serotonin receptors besides the preceding, such as the serotonin 5-HT_2C receptor, were not assessed.¹ The drug was a weak monoamine oxidase inhibitor (MAOI), specifically of monoamine oxidase A (MAO-A) (IC₅₀Tooltip half-maximal inhibitory concentration = 7,252 nM).¹

TACT908 is under development by Tactogen.¹²³ It was patented by Matthew Baggott of Tactogen in 2023.¹ As of January 2025, the drug is in preclinical research for cluster headaches.²³

The α-methyl and N-desmethyl analogue of TACT908, 1ZP2MA ([1-(indolizin-1-yl)propan-2-yl](methyl)amine or 1-(indolizin-1-yl)-N-methylpropan-2-amine), has also been characterized and described.¹ It is the indolizine analogue of α,N-dimethyltryptamine (α,N-DMT or N-methyl-αMT).¹ 1ZP2MA was found to be a potent dopamine releasing agent, with an EC₅₀ of 62 nM.¹